U.S. Hotel and Resort REITs Stock News

Cheniere Energy (NYSE:LNG) is in talks with Thailand to adjust existing LNG contracts to increase and speed up cargo deliveries. The discussions are tied to supply disruptions linked to a force majeure event affecting LNG exports from Qatar. Thailand is seeking more volume and faster arrival of LNG cargoes as it responds to tighter regional gas supply conditions. Cheniere Energy is a major US LNG exporter, with contracts supplying buyers across Asia and Europe. The current talks with...

Why Allegiant Travel Is On Investors’ Radar Allegiant Travel (ALGT) has caught investor attention after recent share price swings, with the stock up about 7% over the past day but showing weaker performance over the past month. See our latest analysis for Allegiant Travel. The sharp 7.2% one-day share price return contrasts with a 28.1% 30-day share price decline and a 9.1% year-to-date share price fall. At the same time, the 1-year total shareholder return of 52.6% highlights how volatile...

In March 2026, CRISPR Therapeutics AG completed a US$550 million Rule 144A offering of 1.7308% senior unsecured convertible notes due March 1, 2031, bolstering its balance sheet for ongoing gene-editing programs. Institutional interest also intensified, with ARK Investment Management increasing its CRISPR Therapeutics stake, underscoring how large investors are positioning around the company’s gene-editing pipeline. Against this backdrop, we’ll examine how the sizeable convertible note...

If you are wondering whether monday.com at US$75.28 still offers value after a rough stretch, the key is understanding what the recent price action is really telling you about expectations. The stock is up 4.0% over the last 30 days but has seen a 3.0% decline over the past week and a much steeper 47.5% drop year to date, with a 70.7% decline over the last year and a 45.4% decline over three years. Recent coverage has focused on how project management and productivity software providers like...

Wondering whether Grab Holdings at around US$3.84 is offering value or just more volatility? This breakdown is designed to help you frame the stock through clear valuation lenses. The share price has seen a 7 day return of 0.8% decline, a 30 day return of 7.0% decline, a year to date return of 24.4% decline and a 1 year return of 16.5% decline, set against a 3 year return of 33.8% and a 5 year return of 69.2% decline. Recent coverage has focused on Grab Holdings as a key player within the US...

If you are wondering whether ANI Pharmaceuticals at around US$74.28 is offering fair value or a potential mispricing, it helps to step back and look at the full return and valuation picture. The share price has seen a 2.2% decline over the past week and a 4.0% decline over the past month, while still recording a 15.7% return over 1 year and an 86.4% and 132.1% return over 3 and 5 years respectively. Recent news coverage has focused on ANI Pharmaceuticals as part of broader discussions around...

2K, a label under Take-Two Interactive Software, has announced WWE 2K26 with expanded editions and new gameplay features. The title is planned for broad platform availability, including tailored support for Nintendo Switch 2 hardware. WWE 2K26 will feature the largest roster in the franchise so far and a slate of post-launch content. For investors tracking NasdaqGS:TTWO, WWE 2K26 arrives as a fresh entry in a key licensed sports entertainment series, adding to Take-Two Interactive...

Timken (TKR) is back on investor radar after recent share price moves, with the stock around US$98.59 and short term performance mixed between daily, weekly and month returns. See our latest analysis for Timken. Recent share price moves at around US$98.59 come after a 30 day share price return of an 8.58% decline, in contrast with a 90 day share price return of 17.17% and a 1 year total shareholder return of 34.41%. This indicates fading short term momentum alongside a stronger longer term...

Embassy Bancorp (EMYB) has posted a clean set of Q3 2025 numbers, with total revenue of US$11.7 million and basic EPS of US$0.50, against a 12 month backdrop where revenue on a trailing basis moved from US$39.8 million to US$44.0 million and EPS from US$1.37 to US$1.68. The latest quarter sits within a year where earnings grew 21.3% versus the longer term trend and sets the stage for investors to focus on how a 29.1% net margin and a 2.58% net interest margin shape the quality and resilience...

In early March 2026, ACI Worldwide launched ACI Connetic for Cards, a next-generation, fully integrated, cloud-native card payments suite within its ACI Connetic platform, unifying account-to-account payments, card processing and AI-driven fraud prevention on a single enterprise-grade hub. This move gives banks and payment providers a modular way to modernize card operations and consolidate issuing, acquiring, ATM and fraud capabilities as global card transaction volumes keep expanding. Now...

Kaspi.kz (NasdaqGS:KSPI) has posted its FY 2025 results with Q4 revenue at KZT 1.1t and net income at KZT 276,983 million, translating into basic EPS of KZT 1,451.81, against a backdrop of trailing 12 month revenue of KZT 4.0t and net income of KZT 1,073,177 million. Over recent periods, the company has seen revenue move from KZT 744,178 million in Q4 2024 to KZT 1,146,548 million in Q4 2025, while quarterly basic EPS shifted from KZT 1,641.41 to KZT 1,451.81 and trailing basic EPS moved from...

Q2 Holdings (NYSE:QTWO) has seen a pattern of insider selling over the past year, with no insider share purchases reported in the same period. Most recently, General Counsel Michael Kerr sold company shares, adding to the ongoing insider selling trend. This activity comes as Q2 Holdings continues to operate as a provider of digital banking and financial experience software for banks and credit unions. Q2 Holdings focuses on cloud based digital banking platforms that help financial...

Black Diamond Therapeutics (BDTX) just posted a sharp swing into profit for FY 2025, with first half revenue of US$70 million translating to basic EPS of US$0.81, compared with losses in both halves of FY 2024. Over the past year, the company has seen revenue move from US$0 to US$70 million while basic EPS has shifted from losses of US$0.71 and US$0.56 in FY 2024 to a trailing 12 month figure of US$0.25. This sets up a results season where investors will focus squarely on how durable these...

Earlier this year, IDEXX Laboratories reported quarterly results that exceeded Wall Street expectations and raised its full-year guidance, underscoring robust demand for its veterinary diagnostic solutions and strength in pet healthcare. This performance highlights how IDEXX’s recurring revenue model and profitable diagnostics business can translate operational momentum into stronger earnings visibility. Next, we’ll examine how this earnings beat and upgraded guidance may reshape IDEXX’s...

Immatics N.V. reported full-year 2025 results showing a net loss of €196.45 million, reversing from net income of €15.22 million in 2024, alongside a shift from earnings per share to a loss per share. At the same time, the company highlighted strong enrollment in its Phase 3 SUPRAME trial for lead therapy anzu-cel (IMA203), underlining how its expanding oncology pipeline is increasingly driving the business story despite recent losses. Against this backdrop, we will examine how progress in...

Stoke Therapeutics (STOK) has reported FY 2025 results that feature a wide range of quarterly outcomes. Q1 revenue was US$158.6 million with EPS of US$1.95, followed by Q2 revenue of US$13.8 million and an EPS loss of US$0.40, and Q3 revenue of US$10.6 million with an EPS loss of US$0.65. Over recent periods the company has seen revenue move between US$4.8 million and US$158.6 million per quarter, while EPS has shifted from a US$2.07 loss in FY 2024 to a US$1.95 profit and then back into...

WW International (WW) has just posted its FY 2025 results with Q3 revenue of US$172.1 million and a basic EPS loss of US$1.04, set against a trailing 12 month net income of about US$1.1 billion that reflects a large one off gain. Over recent quarters the company has seen revenue move between US$184.4 million and US$202.1 million, while EPS has swung from a profit of US$0.31 to a loss of US$0.91 and then a very large profit of US$15.71. This pattern points to margins that appear to be heavily...

Understanding nCino after a prolonged share price slide nCino (NCNO) has seen its share price weaken over the past year, with negative returns over the past month, past 3 months, and year, putting its current US$15.23 level in focus for valuation minded investors. See our latest analysis for nCino. The recent 40.0% three-month share price decline and 38.2% year-to-date share price return reflect fading momentum, while the 46.6% one-year total shareholder return loss highlights how prolonged...

Earlier this week, Savers Value Village reported preliminary fourth-quarter results showing an 8.8% rise in U.S. comparable sales and 0.7% growth in Canada, while President and COO Jubran N. Tanious exercised options for 100,000 shares at US$1.41 and sold 45,000 shares for about US$373,644 on March 11, 2026. This combination of stronger U.S. store performance and fresh insider share activity offers investors new information on both operational momentum and executive incentives. We’ll now...

Q3 2026 snapshot: Value Line (VALU) leans on margins as earnings trends soften Value Line (VALU) has just reported its Q3 2026 results, with recent quarters showing revenue around US$8.6 million and basic EPS between US$0.42 and US$0.69, while trailing twelve month EPS sits a little above US$2.25. Over the last six reported quarters, revenue has ranged from US$8.39 million to US$8.97 million and basic EPS has moved between US$0.42 and US$0.69, setting up a picture where high profitability...

Coya Therapeutics (COYA) has released its FY 2025 results, reporting fourth quarter revenue of US$4.0 million and a basic EPS loss of US$0.34, alongside trailing twelve month revenue of US$7.9 million and a basic EPS loss of US$1.27. The company’s revenue increased from US$0.00 million in the third quarter of 2024 to US$3.6 million in the third quarter of 2025, while quarterly basic EPS has ranged from a loss of US$0.44 in the first quarter of 2025 to a loss of US$0.13 in the third quarter of...

Zomedica (OTCPK:ZOMD.F) has reported its FY 2025 third quarter with total revenue of US$8.1 million and a basic EPS loss of US$0.006, alongside a net loss of US$6.1 million. Over recent quarters, revenue has moved from US$6.1 million in Q2 2024 to US$6.5 million in Q1 2025 and US$8.1 million in Q3 2025, while quarterly net losses have ranged from US$6.1 million to US$63.8 million and trailing twelve month revenue has reached US$29.5 million against a trailing net loss of US$84.5 million. For...

Consolidated Water (CWCO) has put up another solid top line in FY 2025 so far, with Q3 revenue of about US$35.1 million and basic EPS of roughly US$0.35, while the latest trailing twelve months show revenue of about US$130.8 million and EPS of around US$1.09. Over recent periods the company has seen revenue move from roughly US$28.4 million in Q4 2024 to US$35.1 million in Q3 2025, with quarterly EPS shifting from about US$0.11 to US$0.35 over the same stretch. This sets up a story where...

AXT (NasdaqGS:AXTI) reported material insider stock sales by its CEO and a director, alongside an update to revenue guidance. The company lowered revenue expectations after facing reduced export permits for indium phosphide from China. Management continues to emphasize expansion plans and a highly optimistic outlook despite these regulatory and operational challenges. These developments come as AXT trades at $44.36, with the stock showing very large gains of 2,464.2% over the past year and...